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BACKGROUND
Aortic-root dissection is the leading cause of death in Marfan’s syndrome. Studies 
suggest that with regard to slowing aortic-root enlargement, losartan may be more 
effective than beta-blockers, the current standard therapy in most centers.
METHODS
We conducted a randomized trial comparing losartan with atenolol in children and 
young adults with Marfan’s syndrome. The primary outcome was the rate of aortic-
root enlargement, expressed as the change in the maximum aortic-root-diameter 
z score indexed to body-surface area (hereafter, aortic-root z score) over a 3-year 
period. Secondary outcomes included the rate of change in the absolute diameter of 
the aortic root; the rate of change in aortic regurgitation; the time to aortic dissection, 
aortic-root surgery, or death; somatic growth; and the incidence of adverse events.
RESULTS
From January 2007 through February 2011, a total of 21 clinical centers enrolled 
608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in 
the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-
root z score greater than 3.0. The baseline-adjusted rate of change (±SE) in the 
aortic-root z score did not differ significantly between the atenolol group and the 
losartan group (−0.139±0.013 and −0.107±0.013 standard-deviation units per year, 
respectively; P = 0.08). Both slopes were significantly less than zero, indicating a 
decrease in the degree of aortic-root dilatation relative to body-surface area with 
either treatment. The 3-year rates of aortic-root surgery, aortic dissection, death, 
and a composite of these events did not differ significantly between the two treat-
ment groups.
CONCLUSIONS
Among children and young adults with Marfan’s syndrome who were randomly as-
signed to losartan or atenolol, we found no significant difference in the rate of aortic-
root dilatation between the two treatment groups over a 3-year period. (Funded by 
the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, 
NCT00429364.)
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Marfan’s syndrome is an autoso-mal dominant disorder of connective tissue affecting approximately 1 in 
5000 people.1 Cardiovascular disease, mainly 
progressive aortic-root dilatation and dissection, 
is the leading cause of death in Marfan’s syn-
drome. After an open-label, randomized trial 
comparing propranolol with no therapy, pub-
lished in 1994, showed a reduced rate of aortic 
enlargement among treated patients, beta-adren-
ergic receptor antagonists (beta-blockers) became 
the mainstay of medical management.2 Current 
management includes serial cardiac imaging, exer-
cise restriction, administration of beta-blockers, 
and elective aortic-root replacement.3 Although 
early diagnosis and refined medical and surgical 
treatment have improved survival, patients with 
Marfan’s syndrome continue to have high rates 
of cardiovascular disease and early death.
Marfan’s syndrome is caused by mutations in 
FBN1,4 the gene that encodes fibrillin-1, a com-
ponent of extracellular microfibrils. Fibrillin-1 
binds the latent complex of the cytokine trans-
forming growth factor β (TGF-β) and regulates 
its activation and signaling. Studies in a mouse 
model of Marfan’s syndrome showed that a defi-
ciency of fibrillin-1 was associated with excessive 
signaling by TGF-β. Excessive TGF-β activation 
and signaling are currently thought to contrib-
ute to the pleiotropic manifestations of Marfan’s 
syndrome, including aortic-root dilatation and 
dissection.5,6
The angiotensin II type 1–receptor blocker 
(ARB) losartan has been shown to attenuate 
TGF-β signaling in some disease states, such as 
chronic renal failure, presumably by decreasing 
the expression of TGF-β ligands,6,7 receptors,8 
and activators.9 The rate of aortic-root growth 
among mice with Marfan’s syndrome treated 
with losartan was similar to that among wild-
type mice and was significantly less than that 
among untreated littermates with Marfan’s syn-
drome.10 Although the beta-blocker propranolol 
also reduced the rate of aortic-root growth 
among mice with Marfan’s syndrome, this effect 
was much less pronounced than that seen with 
losartan. Losartan therapy in mice with Marfan’s 
syndrome prevented elastic-fiber fragmentation 
and therefore preserved aortic-wall architecture.10 
Losartan also decreased the rate of aortic-root 
dilatation in two small series of children with 
Marfan’s syndrome.11,12 The goal of the present 
trial was to determine whether the rate of aortic-
root enlargement during treatment with losartan 
differs from the rate during treatment with at-
enolol among patients with Marfan’s syndrome 
and a dilated aortic root.
ME THODS
STUDY DESIGN
The study design has been published previous-
ly.13 The trial was designed and performed by the 
Marfan Trial Subcommittee of the Pediatric 
Heart Network (see the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org). The protocol (available at NEJM.org) 
was approved by the institutional review board or 
ethics committee at each study center. The data 
were collected by center investigators and ana-
lyzed at the data coordinating center (New En-
gland Research Institutes). The lead statistician 
(the third author) vouches for the accuracy of the 
data and analyses, and all the authors vouch for 
the fidelity of this report to the trial protocol.
The trial was sponsored by the National 
Heart, Lung, and Blood Institute, with additional 
financial support provided by the Food and Drug 
Administration (FDA) Office of Orphan Products 
Development and the Marfan Foundation. Merck 
and Teva Canada provided losartan and atenolol, 
respectively, but these companies had no role in 
the design or conduct of the trial, data collection 
or analysis, or the writing of the manuscript or 
the decision to submit it for publication.
PARTICIPANTS
Inclusion criteria were an age of 6 months to 25 
years, a diagnosis of Marfan’s syndrome accord-
ing to the original Ghent criteria (Table S1 in the 
Supplementary Appendix),14 and a z score for the 
maximum aortic-root diameter indexed to body-
surface area (hereafter, aortic-root z score) great-
er than 3.0 (as determined by measurement at the 
local study site). Exclusion criteria were previous 
or impending aortic surgery; an aortic-root diam-
eter greater than 5 cm; a history of aortic dissec-
tion; a diagnosis of the Loeys–Dietz syndrome15 
or the Shprintzen–Goldberg syndrome16; thera-
peutic rather than prophylactic use of an angio-
tensin-converting–enzyme inhibitor, beta-blocker, 
or calcium-channel blocker; prior adverse effects 
related to treatment with ARB or beta-blocker 
therapy or a contraindication to such treatment; 
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and an inability to complete study procedures. 
Written informed consent was obtained from 
each participant or the participant’s parent or 
guardian.
STUDY PROCEDURES
Participants were assigned to atenolol or losartan 
in a 1:1 ratio with the use of randomly permuted 
blocks stratified according to age (young adults 
[defined as male participants 16 to 25 years of 
age and female participants 15 to 25 years of age] 
vs. children [male participants younger than 16 
years of age and female participants younger 
than 15 years of age])17 and a baseline aortic-root 
z score of less than 4.5 versus a z score of 4.5 or 
greater. Dynamic allocation was performed with-
in each center.18
Atenolol (at an initial dose of 0.5 mg per kilo-
gram of body weight) was increased on the basis 
of the hemodynamic response up to a maximum 
dose of 4.0 mg per kilogram per day (not to ex-
ceed a total dose of 250 mg), with a goal of a 
20% or greater decrease in the mean heart rate 
as measured on a 24-hour recording.13 Losartan 
(at an initial dose of 0.4 mg per kilogram) was 
adjusted on the basis of body weight up to a 
maximum dose of 1.4 mg per kilogram per day 
(not to exceed a total dose of 100 mg), as recom-
mended by the FDA.13
Study personnel supervising the dose adjust-
ments were aware of the treatment assignments. 
All other persons, including participants, fami-
lies, and other caregivers, were unaware of the 
treatment assignments. Losartan was provided 
by the manufacturer as unmarked white tablets. 
No unmarked tablets were available for atenolol, 
which was provided by the manufacturer as 
white tablets that retained the appearance of the 
commercially available generic agent, so partici-
pants and family members may have determined 
the study-drug assignment. Echocardiographic 
core laboratory readers were unaware of both the 
treatment assignment and the study visit number.
FOLLOW-UP AND OUTCOMES
Study visits occurred at baseline and at 6, 12, 24, 
and 36 months after randomization. Echocardio-
grams were obtained at each study visit and were 
interpreted in a core laboratory. Adherence to 
the treatment regimen was assessed according 
to the number of tablets or amount of liquid in 
the medication bottles that were returned.
The primary outcome was the rate of aortic-
root enlargement, expressed as the annual change 
in the aortic-root z score, measured by means of 
echocardiography as previously described,19 over 
the 3-year period after randomization. Secondary 
outcomes included the rate of change in the 
absolute diameter of the aortic root; the rate of 
change in the z score and the absolute diameter 
of the ascending aorta and the aortic annulus; 
the rate of change in aortic regurgitation; time 
to aortic dissection, aortic-root surgery, or death 
(clinical outcomes); the rate of change in anthro-
pometric outcomes (height, weight, body-mass 
index, ratio of upper to lower body segment, 
and ratio of arm span to height); and the inci-
dence of adverse events and participant-reported 
symptoms.
STATISTICAL ANALYSIS
We designed the trial to have, with an alpha level 
of 0.05, 85% power to detect a treatment differ-
ence of 0.194 standard-deviation units (z score 
units) per year13 in the aortic-root z score, after 
adjustment for treatment crossover, an assumed 
withdrawal rate of up to 20%, and three interim 
analyses. The resulting target sample was 604 
participants.
The primary analysis was based on the inten-
tion-to-treat principle. Secondary analyses were 
performed with the use of multiple imputation 
for missing data, as well as with the exclusion of 
36 participants who were identified after random-
ization as having a major eligibility violation, 
and with adjustment for status with respect to a 
history of an endocrine disorder, because the 
prevalence of this baseline characteristic was 
unequal in the two treatment groups. A nominal 
P value of less than 0.0453 was required for the 
two-sided analysis of the primary outcome at the 
completion of the trial because three interim 
analyses were performed. Adjustments were not 
made to the significance levels of hypothesis 
tests for secondary trial outcomes.
Echocardiographic and anthropometric out-
comes were modeled with linear regression with 
the use of mixed effects to account for the lon-
gitudinal design,20 with the use of compound 
symmetry and unstructured covariance struc-
tures, respectively. The baseline-adjusted rates of 
change in the two treatment groups were com-
pared with the use of a test of the treatment-by-
time interaction effect. Linear regression was 
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used to examine the relationship between heart 
rate and prescribed dose. The time to clinical 
events according to treatment group and accord-
ing to subgroup for all the participants was 
compared with the use of a log-rank test, with 
event rates estimated according to the Kaplan–
Meier method. The incidence rates of adverse 
events in the two treatment groups were com-
pared with the use of Poisson regression. Treat-
ment-group comparisons of blood pressure, heart 
rate, and safety-related laboratory variables were 
performed with the use of Student’s t-test or a 
Wilcoxon rank-sum test, and treatment-adher-
ence rates and proportions of participants with 
each reported drug reaction were compared with 
the use of Fisher’s exact test.
The prespecified subgroups defined at base-
line were young adults versus children, age as a 
continuous variable, aortic-root z score (<4.5 vs. 
≥4.5), and previous use of a beta-blocker (yes vs. 
no). A differential treatment effect according to 
prespecified subgroup was identified by an inter-
action test (subgroup by treatment by time) in 
the longitudinal regression model for the echo-
cardiographic and anthropometric outcomes and 
in a Cox proportional-hazards regression model 
for clinical outcomes.
R ESULT S
STUDY PARTICIPANTS
From January 2007 through February 2011, we 
enrolled 608 participants at 21 clinical centers; 
303 participants were randomly assigned to ateno-
lol and 305 to losartan. The numbers of patients 
who were screened, randomly assigned to a treat-
ment group, and included in the analysis of the 
primary outcome are shown in Figure 1. Baseline 
clinical and echocardiographic characteristics 
were similar between the atenolol group and the 
losartan group, except for the incidence of endo-
crine disorders (2% vs. 0%, P = 0.007) (Table 1).19,21 
There was no significant difference in the with-
drawal rate (11% in each group) or in the median 
time from randomization to withdrawal (2.3 years 
in the atenolol group and 1.9 years in the losar-
tan group, P = 0.47).
PRESCRIBED DOSE AND ADHERENCE
The mean dose of atenolol was 2.7±1.1 mg per 
kilogram per day, and the mean dose of losartan 
was 1.3±0.2 mg per kilogram per day (Table S2 in 
the Supplementary Appendix). The mean abso-
lute doses for young adults were 151±75 mg of 
atenolol per day and 85±14 mg of losartan per day. 
The proportion of patients who returned at least 
60% of medication bottles did not differ signifi-
cantly between the atenolol group and the losar-
tan group (65% and 64%, respectively; P = 0.86). 
On the basis of the amount of medication in the 
bottles returned, we estimated that 71% of the 
participants took at least 80% of the dispensed 
dose (73% of the participants in the atenolol 
group and 69% in the losartan group, P = 0.30).
BLOOD-PRESSURE AND HEART-RATE EFFECTS
There were no significant differences between the 
two treatment groups in baseline blood pressure 
(Table S3 in the Supplementary Appendix). At 
3 years, there was a small but significant difference 
in the mean diastolic pressure (54±8 mm Hg in 
the atenolol group vs. 56±8 mm Hg in the losar-
tan group, P = 0.04) but no significant differences 
in the systolic pressure or mean blood pressure 
(Table S3 in the Supplementary Appendix).
As expected, the resting and average 24-hour 
heart rates were significantly lower at all study 
visits in the atenolol group than in the losartan 
group (Table S3 in the Supplementary Appendix). 
Among children, higher prescribed doses of aten-
olol were significantly associated with higher 
resting and average 24-hour heart rates, suggest-
ing a relative lack of heart-rate responsiveness in 
some participants during the dose-adjustment 
process (Fig. S1 in the Supplementary Appendix).
AORTIC-GROWTH OUTCOMES
The baseline-adjusted annual rate of change 
(±SE) in the aortic-root z score did not differ sig-
nificantly between the atenolol group and the 
losartan group (−0.139±0.013 and −0.107±0.013 
standard-deviation units per year, respectively; 
P = 0.08) (Fig. 2A and Table 2). Both slopes were 
significantly less than zero, indicating a decrease 
in the aortic-root z score in the two treatment 
groups. There was insufficient evidence to de-
clare a differential treatment effect according to 
any prespecified subgroup analyses (Fig. S2 and 
S3 in the Supplementary Appendix), including 
age as a continuous variable (P = 0.38 for interac-
tion) and an alternative definition of young adult 
versus child13 that was based on attainment of 
maximal height (P = 0.38 for interaction).
A younger age at baseline was associated with 
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608 Underwent randomization
701 Were assessed for eligibility
43 Were eligible but did not undergo
randomization
22 Declined to participate
20 Were ineligible on the basis of
echocardiographic or laboratory results
1 Withdrew consent
50 Were ineligible
38 Did not meet Ghent criteria
12 Had Loeys–Dietz syndrome or
Shprintzen–Goldberg syndrome
1367 Patients underwent medical-record
review
433 Were ineligible for screening
233 Declined screening
303 Were assigned to atenolol 305 Were assigned to losartan
32 Withdrew from trial
10 Underwent surgery
11 Withdrew consent
4 Were withdrawn by
physician
5 Were lost to follow-up
2 Had other reason
33 Withdrew from trial
18 Underwent surgery
1 Died
5 Withdrew consent
2 Were withdrawn by
physician
6 Were lost to follow-up
1 Had other reason
268 Were followed for 3 yr 267 Were followed for 3 yr
271 Remained in trial
253 Continued taking study drug
18 Discontinued study drug
2 Received open-label atenolol
1 Received open-label carvedilol
2 Received open-label losartan
13 Did not take beta-blocker or 
ARB
272 Remained in trial
264 Continued taking study drug
8 Discontinued study drug
3 Received open-label atenolol
1 Received open-label losartan
4 Did not take beta-blocker or 
ARB
Figure 1. Screening, Randomization, and Follow-up.
The most common exclusion criterion during the medical-record review (71% of records reviewed) was an aortic-
root-diameter z score of less than 3.0. Among the 543 participants who remained in the trial, data for the primary 
end point at 3 years were available for all but 11, who had unacceptable or missing echocardiograms (5 participants 
in the atenolol group and 6 in the losartan group). In addition, 3 participants withdrew late from the study (2 partic-
ipants in the atenolol group because of aortic-root surgery and 1 in the losartan group because of unplanned preg-
nancy); the echocardiograms obtained at the time of withdrawal for these 3 participants served as the 3 year measure-
ments, yielding a total of 535 participants with data for the primary end point at 3 years (268 participants in the 
atenolol group and 267 in the losartan group). ARB denotes angiotensin II–receptor blocker.
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a greater decrease in the aortic-root z score over 
time in the atenolol group (P<0.001) and in the 
losartan group (P = 0.002), without a significant 
difference between the treatment groups (P = 0.38 
for interaction) (Table S4 in the Supplementary 
Appendix). The annual change in the aortic-root 
z score in children and young adults did not vary 
according to the prescribed dose (P = 0.51 for 
Table 1. Demographic and Clinical Characteristics at Baseline.*
Characteristic
Atenolol
(N = 303)
Losartan
(N = 305)
Age — yr 11.5±6.5 11.0±6.2
Young adult — no. (%)† 76 (25) 75 (25)
Male sex — no. (%) 180 (59) 186 (61)
Race — no. (%)‡
White 266 (88) 260 (85)
Black 21 (7) 25 (8)
Asian 6 (2) 10 (3)
Other 10 (3) 10 (3)
Hispanic — no./total no. (%)‡ 36/302 (12) 46/305 (15)
Presence of causal FBN1 mutation — no. (%)
Yes 93 (31) 88 (29)
No 9 (3) 15 (5)
Unknown 201 (66) 202 (66)
Family history of Marfan’s syndrome — no./total no. (%) 180/295 (61) 181/290 (62)
Echocardiographic findings§
Maximum aortic-root diameter — cm 3.4±0.7 3.4±0.7
Maximum aortic-root-diameter z score
Median 4.0 4.0
Interquartile range 3.5–4.8 3.3–5.0
≥4.5 — no./total no. (%) 106/303 (35) 114/304 (38)
Medical history — no. (%)
Cardiac surgery 6 (2) 6 (2)
Cardiovascular disorder¶ 39 (13) 36 (12)
Prior use of beta-blocker 173 (57) 171 (56)
Endocrine disorder‖ 7 (2) 0
Neurodevelopmental disorder** 56 (18) 61 (20)
Psychiatric disorder†† 23 (8) 16 (5)
* Data are adapted from Lacro et al.21 Plus–minus values are means ±SD. The demographic and clinical characteristics 
did not differ significantly between the two treatment groups (P>0.20 for all comparisons), with the exception of a his-
tory of an endocrine disorder (P = 0.007).
† Young adults were defined as male participants who were 16 to 25 years of age and female participants who were 15 
to 25 years of age.
‡ Race or ethnic group was reported by the participant or a family member at the time of enrollment.
§ Data are based on readings at a central echocardiographic laboratory. Echocardiographic data were missing for one 
participant in the losartan group because of an unreadable echocardiogram.
¶ Cardiovascular disorder was defined by exercise intolerance; syncope; arrhythmia, hypertension, or hypotension requiring 
therapy; chest pain; shortness of breath; or other cardiovascular conditions.
‖ Endocrine disorder was defined by either the use of hormone therapy to limit growth or delayed puberty.
** Neurodevelopmental disorder was defined as attention deficit–hyperactivity disorder requiring therapy, developmental 
delay requiring therapy, learning disability requiring services, or other neurodevelopmental conditions.
†† Psychiatric disorder was defined as depression requiring therapy, anxiety, or other psychiatric conditions.
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interaction in the atenolol group; P = 0.78 for 
interaction in the losartan group) (Table S5 in 
the Supplementary Appendix).
The average annual rate of change in the ab-
solute diameter of the aortic root was similar in 
the two treatment groups (Table 2 and Fig. 2B). 
There were small but significant differences favor-
ing atenolol in the average annual change in the 
absolute diameter and z score for the aortic an-
nulus, but there were no significant differences 
in the diameter or z score for the ascending 
aorta (Table 2). The results of the secondary 
analyses of the aortic-root z score and data on the 
anthropometric outcomes are shown in Tables 
S6, S7, and S8 in the Supplementary Appendix.
ADVERSE CLINICAL OUTCOMES
The 3-year rates of aortic-root surgery, aortic dis-
section, death, and a composite of these events 
did not differ significantly between the two treat-
ment groups (Fig. 3 and Table 2), nor did the 
treatment effect depend on subgroup. Additional 
clinical information regarding participants with 
these events is provided in the Supplementary 
Appendix. In an analysis that combined the two 
treatment groups, the 3-year rate of aortic-root 
surgery was approximately 2 times as high among 
young adults as among children (8.5% vs. 3.8%, 
P = 0.03) and approximately 15 times as high 
among participants with a baseline aortic-root 
z score of 4.5 or greater as among those with a 
z score of less than 4.5 (12.2% vs. 0.8%, P<0.001).
ADVERSE EVENTS AND PARTICIPANT-REPORTED 
SYMPTOMS
There was no significant difference between the 
atenolol group and the losartan group in the over-
all rate of adverse events (408 events and 365 events, 
respectively; P = 0.10) or serious adverse events 
(40 events and 50 events, respectively; P = 0.31). 
The rate of adverse events that were possibly or 
probably related to the study drug was higher 
with atenolol than with losartan (204 events vs. 
163 events, P = 0.03), but the results did not differ 
significantly when the analysis was restricted to 
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Figure 2. Change in Aortic-Root z Score and Aortic-
Root Diameter, According to Treatment Group.
The aortic-root z score is the z score for the maximum 
diameter of the aortic root, indexed to body-surface 
area. Panel A shows the baseline-adjusted rate of change 
in the aortic-root z score over the 3-year period (solid 
lines), with 95% confidence intervals (dashed lines) for 
the pointwise comparison. Panel B shows the baseline-
adjusted rate of change in the maximum diameter of 
the aortic root over the 3-year period (solid lines), with 
95% confidence intervals (dashed lines) for the point-
wise comparison.
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serious adverse events (5 events and 2 events, re-
spectively; P = 0.25). Further information about 
adverse events and patient-reported symptoms is 
provided in Table S9 in the Supplementary Ap-
pendix.
DISCUSSION
In this randomized trial comparing losartan 
with atenolol in a large cohort of children and 
young adults with Marfan’s syndrome and a di-
lated aortic root, we found no significant differ-
ence in the rate of aortic-root dilatation, indexed 
to body-surface area, between the two treatment 
groups over a 3-year period. The effects of treat-
ment with these agents also did not differ sig-
nificantly according to prespecified subgroups, 
including younger versus older participants. We 
did not find the expected advantage of ARB ther-
apy over beta-blocker therapy. However, we found 
a small but significant difference in favor of 
aten olol with regard to the absolute diameter and 
z score for the aortic annulus. This finding was 
unexpected, without a clear physiological expla-
nation.
The dose of the beta-blocker used in this 
study was higher than that used in many other 
studies. The dose of atenolol was adjusted for a 
physiological effect, and the rate of change in 
the aortic-root z score was not related to dose. 
The dose of losartan reflected FDA recommen-
dations at the time of protocol development and 
was in a much narrower range than the dose of 
atenolol. A higher dose of losartan or a different 
ARB might have shown a greater effect on aortic 
growth rate. We also found that diastolic blood 
pressure was slightly but significantly lower in 
the atenolol group than in the losartan group, an 
effect that could reduce the aortic growth rate 
and perhaps counter the effect of ARB-induced 
suppression of TGF-β signaling in the losartan 
group.
Although the rate of change in the aortic-root 
z score did not differ significantly between the 
two treatment groups, the aortic-root z score 
decreased significantly over time in each group, 
particularly in younger versus older participants, 
which suggests that there may be value in begin-
ning therapy relatively early in the disease 
course. Without a placebo group, we are not able 
to evaluate the magnitude of this benefit, al-
though a previous study comparing beta-block-
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ers with placebo2 offers a basis for the conclu-
sion that both agents are effective. The low rate 
of bothersome participant-reported symptoms is 
an important finding for both patients and their 
medical providers because therapy can be selected 
on the basis of individual patient and provider 
preference.
There are methodologic differences between 
our study and other, smaller studies that have 
shown a benefit of losartan therapy. These in-
clude a direct comparison of losartan with a 
beta-blocker in our study versus comparison of a 
combination therapy with a beta-blocker alone 
in other studies,22,23 similar blood pressures ver-
sus differential lowering in the treatment groups,23 
the inclusion of both children and young adults 
versus adults alone, and the exclusion of patients 
with prior aortic surgery versus the inclusion of 
such patients.23 In one study involving a small 
number of participants, most of whom were 
children, combined open-label losartan and beta-
blocker therapy decreased the rate of aortic-root 
dilatation more than did beta-blocker therapy 
alone.22 The target doses of the beta-blocker 
administered (maximum dose, 150 mg per day 
in adults and 2 mg per kilogram per day in chil-
dren) were smaller than in our study, and the 
exact doses achieved were not reported.22 In 
contrast to the patient population in a retrospec-
tive study reported by Brooke et al.,11 which 
showed a marked beneficial effect of an ARB 
plus beta-blockers as compared with previous 
therapy with beta-blockers alone, our study 
population had a higher average age, the average 
aortic-root z score was lower, and the beta-
blocker dose was higher.11 Other trials of thera-
py in patients with Marfan’s syndrome are cur-
rently under way.24-28
This trial had several limitations. First, we 
did not assess the effect of losartan therapy on 
TGF-β. Second, the study results may not be 
generalizable to persons with Marfan’s syn-
drome who have a body-surface area–adjusted 
aortic-root z score of 3.0 or less. Third, the sta-
tistical power of the study was limited for the 
detection of significant subgroup findings and 
treatment differences for relatively low rates of 
clinical events. Fourth, the primary outcome 
was assessed by core laboratory personnel who 
were unaware of the treatment assignments; 
however, personnel supervising the study-drug 
adjustments were aware of the treatment assign-
ments, and some participants may have discov-
ered their treatment assignment on the basis of 
the appearance of the study drug. Finally, we 
recognize the limitations of a surrogate end 
point but believed a trial with a hard clinical end 
point to be impractical, given the rarity of aortic 
dissection or the need for aortic surgery in 
young patients.
In conclusion, this trial involving children and 
young adults with Marfan’s syndrome and aortic-
root dilatation did not show the expected advan-
tages of losartan over atenolol. The rate of 
change in the aortic-root z score over the 3-year 
period did not differ significantly between the 
atenolol group and the losartan group.
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Group.
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comparison. A total of 543 participants completed the 3-year follow-up visit 
(mean follow-up, 3.0±0.1 years). The inset shows the same data on an en-
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